This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Hiromi Kojima, MD; Minoru Iida, MD; Hidemi Miyazaki, MD; Tomohiko Koga, MT; Hiroshi Moriyama, MD; Yoshinobu Manome, MD

Arch Otolaryngol Head Neck Surg. 2002;128:708-713.

Background  Cytarabine is the most effective agent known for the treatment of acute myeloid leukemia. Its antitumor effect is expressed by combining with DNA during replication and then destroying the DNA chain. However, cytarabine has only limited activity against most solid tumors, including squamous cell carcinoma of the head and neck. The reason for this is thought to be that in cell lines of solid tumors the expression of cytidine deaminase, an enzyme that degrades cytarabine, is high, whereas the expression of deoxycytidine kinase (dCK), which phosphorylates cytarabine (a prodrug), is weak.

Objective  To determine whether head and neck squamous cell carcinomas can be made more sensitive to the cytotoxic effects of cytarabine by shifting the balance from the degradative to the activation pathway.

Methods  Human SCC-25 squamous carcinoma cells were transfected by either retroviral vector or adenoviral vector containing DCK gene and were identified for dCK expression by Northern blot analysis. In vitro cytotoxic assay after cytarabine exposure was performed using these cells.

Results  Both retroviral and adenoviral vector-mediated transduction of the dCK complementary DNA resulted in marked sensitization of tongue squamous carcinoma cell lines to the cytotoxic effects of cytarabine in vitro.

Conclusion  The dCK-cytarabine system may be a useful approach for gene therapy of squamous cell carcinomas of the head and neck.

From the Departments of Otorhinolaryngology (Drs Kojima, Iida, Miyazaki, and Moriyama) and Microbiology (Dr Manome), Jikei University School of Medicine, Tokyo, Japan, and the Division of Clinical Laboratory, Chiba Social Insurance Hospital, Chiba, Japan (Dr Koga).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2002;128(6):726-728.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene.
Kojima et al.
Arch Otolaryngol Head Neck Surg 2006;132:682-685.
ABSTRACT | FULL TEXT